Imavita
Imavita is an innovative preclinical CRO specializing in advanced imaging and biomarker analysis. They assist pharma, biotech, and research labs in assessing the safety and efficacy of new therapies using precise, non-invasive tools across in vivo, in vitro, and ex vivo models. Their mission is to provide tailored preclinical models and imaging solutions to better mimic human disease mechanisms, accelerate R&D, and support scientific advancements in various medical fields.
Industries
Nr. of Employees
small (1-50)
Imavita
Products
Automated epidermis thickness quantification algorithm
Image analysis algorithm that segments surface tissue OCT images and computes epidermis thickness; validated by correlation with histology.
Automated epidermis thickness quantification algorithm
Image analysis algorithm that segments surface tissue OCT images and computes epidermis thickness; validated by correlation with histology.
Services
Design and run tailored in vivo, in vitro and ex vivo preclinical studies to assess efficacy, safety and pharmacokinetics for drug candidates and devices.
Multimodal in vivo and ex vivo imaging services including fluorescence tomography, bioluminescence, OCT, PET/CT and associated quantitative image analysis.
Bioinformatics and image analysis pipelines for automated segmentation, biomarker extraction and statistical reporting; validation against histology where relevant.
Support for synthesis, purification and production of F-18 radiolabeled compounds for preclinical injection and development toward pharmaceutical-quality production for clinical use, within collaborative projects.
Execution of endpoint assays including qPCR, ELISA, lipidomics and histology to support mechanism-of-action and validation studies.
Design and run tailored in vivo, in vitro and ex vivo preclinical studies to assess efficacy, safety and pharmacokinetics for drug candidates and devices.
Multimodal in vivo and ex vivo imaging services including fluorescence tomography, bioluminescence, OCT, PET/CT and associated quantitative image analysis.
Bioinformatics and image analysis pipelines for automated segmentation, biomarker extraction and statistical reporting; validation against histology where relevant.
Support for synthesis, purification and production of F-18 radiolabeled compounds for preclinical injection and development toward pharmaceutical-quality production for clinical use, within collaborative projects.
Execution of endpoint assays including qPCR, ELISA, lipidomics and histology to support mechanism-of-action and validation studies.
Expertise Areas
- Preclinical model development and in vivo pharmacology
- Preclinical imaging and image-based biomarker development
- Quantitative image analysis and bioinformatics
- Pharmacokinetics and biodistribution studies
Key Technologies
- Fluorescence molecular tomography (FMT)
- Bioluminescence imaging (BLI) and BLI tomography
- Planar fluorescence imaging (FLI)
- Optical Coherence Tomography (OCT)
News & Updates
Imavita joins a 3-year collaborative project focusing on oncology, cardiovascular, and neurology, developing radiolabeled molecules and preclinical models.
A joint study by Imavita and Ipsen compares effects of botulinum toxin in dermatology models, highlighting skin rejuvenation and anti-inflammatory properties.
Imavita was approved as an Innovative New Company (JEI) by French authorities in September 2013, recognizing its capacity for R&D projects.
Imavita joins a 3-year collaborative project focusing on oncology, cardiovascular, and neurology, developing radiolabeled molecules and preclinical models.
A joint study by Imavita and Ipsen compares effects of botulinum toxin in dermatology models, highlighting skin rejuvenation and anti-inflammatory properties.
Imavita was approved as an Innovative New Company (JEI) by French authorities in September 2013, recognizing its capacity for R&D projects.